NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is inves

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin

REGENXBIO Inc. (NASDAQ:RGNX) on Saturday shared long-term clinical trial findings for its experiment

REGENXBIO announced positive long-term sura-vec trial data for wet AMD and diabetic retinopathy, alo

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinop

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to th

Nasdaq falls over 200 points, Dow down 0.28%, S&P 500 drops 0.51%. Energy shares up 1.4%, commun

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s

U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings

NFLX: 10% | Netflix shares are trading lower after the company reported worse-than-expected Q2 sales

ROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pric

Callan JMB Inc (CJMB) shares jumped 63.8% in pre-market trading after announcing a strategic partner

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-

ROCKVILLE, Md., July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Societ

New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Societ

REGENXBIO upgraded to 'Strong Buy' on FDA's course reversal for rare disease therapies, notably impa

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D

HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintai

Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator

Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator

RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II

Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the pr

Leerink Partners analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Outperform and ra

Regenxbio Inc. (NASDAQ:RGNX) on Monday said it aligned with the Food and Drug Administration (FDA) r

FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap

REGENXBIO Inc. (NASDAQ:RGNX) today announced it has aligned with the U.S. Food and Drug Administrati

FDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE ® study w

SAGT: 124% | Sagtec Global CEO's 1.5M Share Acquisition And $1.56M Private Placement Coincide Wi

The ​U.S. Food ‌and Drug ​Administration ​will reverse ⁠its ​earlier ​rejection of a ​rare-disease ​

The company plans to refile its application for its gene therapy for a fatal brain disease after the

REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

ROCKVILLE, Md., May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will p

REGENXBIO Inc. (RGNX) Q1 2026 Earnings Call Transcript

REGENXBIO Inc. (NASDAQ:RGNX) on Thursday released topline and interim functional data from the pivot

US stocks up, Dow gains 250+ pts. Tech sector up 0.8%, healthcare down 0.3%. Retail sales rise 0.5%

Regenxbio (RGNX) came out with a quarterly loss of $1.72 per share versus the Zacks Consensus Estima

FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer